IDO1 and neoplasm: An active role of apo-IDO1 in tumor progression was described for the first time in a preclinical model of glioblastoma (13), as well as of melanoma (14), where the non-enzymatic mutant of IDO1 respectively suppresses the anti-tumor immunity and triggers the intrinsic cancer cell proliferation, both independently of the catalytic activity (14).